Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non–Small Cell Lung Cancer

医学 肿瘤科 内科学 辅助治疗 肺癌 阶段(地层学) 微小残留病 佐剂 疾病 靶向治疗 指南 化疗 表皮生长因子受体 危险系数 循环肿瘤DNA 辅助化疗 外科 比例危险模型 风险因素 癌症 生存分析 肺 队列 呼吸道疾病 全肺切除术 全身疗法 癌 回顾性队列研究
作者
Siyu Lei,Yaning Yang,Wenxin Jiang,Haiyan Xu,Yousheng Mao,Yan Wang
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号:10 (5): e2500977-e2500977 被引量:4
标识
DOI:10.1200/po-25-00977
摘要

PURPOSE Circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) detection has become a strong prognostic stratification factor in postoperation non–small cell lung cancer (NSCLC). Here, we sought to investigate the guiding potential of MRD in informing adjuvant therapy (AT) decisions. MATERIALS AND METHODS Patients with stage IA to IIIB NSCLC who had undergone confirmed R0 resection were enrolled. Blood samples were collected 1 month after surgery before initiation of AT (landmark) and longitudinally every 3-6 months since surgery. Postoperative AT was conducted according to the guideline recommendations, and regular radiographical examinations were recommended for relapse surveillance. MRD detection was conducted using the MinerVa platform (Genecast Precision Diagnostic Co., Ltd. Wuhan, China) using a tumor-informed strategy based on a fixed next-generation sequencing panel spanning 769 cancer-related genes. RESULTS One hundred sixty-five patients were included in this study, with 35 (21.2%) relapses. At landmark, positive MRD was associated with shorter disease-free survival (DFS) than negative MRD ( P < .001, hazard ratio, 12.0). MRD was an independent risk factor for shorter DFS, irrespective of the disease stage and high-risk factors. In the case of negative landmark MRD, there was no significant difference between the DFS of (1) those who received AT and those who did not in stage IB patients with high-risk factors ( P = .974), (2) epidermal growth factor receptor ( EGFR )–mutant patients with or without adjuvant chemotherapy before adjuvant targeted therapy ( P = .502), and (3) EGFR / ALK wild-type with or without adjuvant immunotherapy ( P = .534). Clearance of ctDNA during AT was associated with a better prognosis than persistently detected ctDNA ( P < .001). CONCLUSION ctDNA-based MRD stratifies prognosis after curative resection in NSCLC, with MRD negativity indicating limited benefit from treatment in selected patients and ctDNA clearance reflecting improved outcomes. These findings support the clinical utility of MRD-guided adjuvant treatment strategies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hinsir发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
wenqing发布了新的文献求助30
3秒前
3秒前
4秒前
兴奋的井完成签到,获得积分20
5秒前
5秒前
5秒前
5秒前
5秒前
5秒前
6秒前
汪博士发布了新的文献求助30
6秒前
奶黄包完成签到 ,获得积分10
7秒前
Lingmei发布了新的文献求助10
7秒前
荼蘼发布了新的文献求助10
8秒前
WELVIRA完成签到,获得积分20
8秒前
zzzz发布了新的文献求助10
8秒前
共享精神的应助被bai采纳,获得10
8秒前
Ssssssinan的应助被拉基采纳,获得10
9秒前
念心驳回了慕青的应助
9秒前
飞奔的水煮蛋完成签到,获得积分10
9秒前
9秒前
9秒前
9秒前
Piggy发布了新的文献求助10
10秒前
CHEN完成签到,获得积分0
10秒前
liuuuuuu完成签到,获得积分10
10秒前
11秒前
11秒前
科目三的应助被abib采纳,获得10
12秒前
pluto的应助被gx采纳,获得10
12秒前
12秒前
12秒前
13秒前
送你一颗流星完成签到,获得积分10
14秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175142
求助须知:如何正确求助?哪些是违规求助? 9566928
关于积分的说明 21789123
捐赠科研通 7769522
什么是DOI,文献DOI怎么找? 3431822
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477222